G01N 2333/515
Angiogenesic factors
Official title: Angiogenesic factors; Angiogenin
G01N2333/515 (Angiogenesic factors) appears on 107 US grants and 219 published applications in this corpus.
Search patents in G01N- Granted patents
- 107
- Published applications
- 219
- Assignees
- 139
- Inventors
- 506
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 4 |
| 2003 | 0 | 3 |
| 2004 | 0 | 6 |
| 2005 | 1 | 11 |
| 2006 | 1 | 15 |
| 2007 | 4 | 7 |
| 2008 | 3 | 14 |
| 2009 | 6 | 10 |
| 2010 | 7 | 16 |
| 2011 | 8 | 12 |
| 2012 | 3 | 6 |
| 2013 | 9 | 12 |
| 2014 | 6 | 11 |
| 2015 | 10 | 20 |
| 2016 | 7 | 8 |
| 2017 | 7 | 5 |
| 2018 | 7 | 9 |
| 2019 | 4 | 8 |
| 2020 | 3 | 8 |
| 2021 | 4 | 7 |
| 2022 | 4 | 4 |
| 2023 | 1 | 5 |
| 2024 | 5 | 5 |
| 2025 | 3 | 9 |
| 2026 | 2 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Conjugates comprising ocular angiogenesis growth factor aptamers and uses thereof in the detection and treatment of ophthalmological angiogenesis indications2 Jun 2026US 12,642,867 B2Bar-Ilan University
- Biomarkers for risk prediction of mortality6 Jan 2026US 12,517,139 B2Roche Diagnostics Operations, Inc.
- Anti-TIE2 antibody and use thereof18 Nov 2025US 12,473,366 B2Pharmabcine Inc.
- Method of assessing wound healing potency of a mesenchymal stem population and related methods of selecting mesenchymal stem cells and identifying tissue as starting material for producing a mesenchymal stem cell population21 Oct 2025US 12,449,413 B2Cellresearch Corporation Pte. Ltd.
- System for detecting infection in synovial fluid12 Aug 2025US 12,385,909 B2CD Diagnostics, Inc.
- Method of treating heart failure in subjects with persistent inflammation16 Jul 2026US 2026/0199396 A1Mesoblast International Sarl
- Molecular signatures to predict long-term liver fibrosis progression2 Jul 2026US 2026/0185169 A1Board of Regents, The University of Texas System
- Method of assessing wound healing potency of a mesenchymal stem population and related methods of selecting mesenchymal stem cells and identifying tissue as starting material for producing a mesenchymal stem cell population2 Jul 2026US 2026/0185978 A1Cellresearch Corporation Pte. Ltd.
- Tropnin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction27 Nov 2025US 2025/0362308 A1Roche Diagnostics Operations, Inc.
- System for detecting infection in synovial fluid6 Nov 2025US 2025/0341519 A1CD Diagnostics, Inc.
Most cited
By later US patents
- Dual variable domain immunoglobulins and uses thereof55US 9,029,508 B2AbbVie Inc. · 2015
- HPTPbeta as a target in treatment of angiogenesis mediated disorders53US 7,226,755 B1The Procter & Gamble Company · 2007
- Use of neomycin for treating angiogenesis-related diseases40US 6,482,802 B1The Endowment for Research in Human Biology, Inc. · 2002
- Compositions and methods for promoting angiogenesis38US 7,462,593 B22008
- Pharmaceutical compositions that modulate HPTPbeta activity33US 7,632,862 B2The Procter & Gamble Company · 2009